Sean Lavin
Stock Analyst at BTIG
(3.05)
# 1,208
Out of 5,241 analysts
37
Total ratings
77.78%
Success rate
33.18%
Average return
Main Sectors:
Stocks Rated by Sean Lavin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TCMD Tactile Systems Technology | Downgrades: Neutral | n/a | $22.74 | - | 4 | Nov 5, 2024 | |
| PODD Insulet | Upgrades: Buy | $320 | $147.46 | +117.01% | 5 | Feb 3, 2022 | |
| MDT Medtronic | Downgrades: Neutral | n/a | $76.15 | - | 1 | Jan 10, 2022 | |
| ATRC AtriCure | Maintains: Buy | $42 → $48 | $28.12 | +70.70% | 3 | Feb 19, 2020 | |
| MASI Masimo | Downgrades: Neutral | n/a | $178.44 | - | 4 | Apr 16, 2019 | |
| HSDT Solana Company | Downgrades: Neutral | n/a | $2.30 | - | 4 | Apr 16, 2019 | |
| IRTC iRhythm Holdings | Upgrades: Buy | $80 | $114.00 | -29.82% | 3 | Apr 3, 2019 | |
| NEO NeoGenomics | Upgrades: Outperform | n/a | $8.24 | - | 4 | Apr 16, 2018 | |
| ABT Abbott Laboratories | Downgrades: Neutral | n/a | $84.47 | - | 1 | Jan 22, 2018 | |
| BSX Boston Scientific | Upgrades: Buy | n/a | $52.68 | - | 1 | Nov 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $61.63 | - | 3 | May 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $81.38 | - | 4 | Feb 2, 2017 |
Tactile Systems Technology
Nov 5, 2024
Downgrades: Neutral
Price Target: n/a
Current: $22.74
Upside: -
Insulet
Feb 3, 2022
Upgrades: Buy
Price Target: $320
Current: $147.46
Upside: +117.01%
Medtronic
Jan 10, 2022
Downgrades: Neutral
Price Target: n/a
Current: $76.15
Upside: -
AtriCure
Feb 19, 2020
Maintains: Buy
Price Target: $42 → $48
Current: $28.12
Upside: +70.70%
Masimo
Apr 16, 2019
Downgrades: Neutral
Price Target: n/a
Current: $178.44
Upside: -
Solana Company
Apr 16, 2019
Downgrades: Neutral
Price Target: n/a
Current: $2.30
Upside: -
iRhythm Holdings
Apr 3, 2019
Upgrades: Buy
Price Target: $80
Current: $114.00
Upside: -29.82%
NeoGenomics
Apr 16, 2018
Upgrades: Outperform
Price Target: n/a
Current: $8.24
Upside: -
Abbott Laboratories
Jan 22, 2018
Downgrades: Neutral
Price Target: n/a
Current: $84.47
Upside: -
Boston Scientific
Nov 30, 2017
Upgrades: Buy
Price Target: n/a
Current: $52.68
Upside: -
May 3, 2017
Downgrades: Neutral
Price Target: n/a
Current: $61.63
Upside: -
Feb 2, 2017
Downgrades: Neutral
Price Target: n/a
Current: $81.38
Upside: -